Cargando…

Molecular Tweezers Targeting Transthyretin Amyloidosis

Transthyretin (TTR) amyloidoses comprise a wide spectrum of acquired and hereditary diseases triggered by extracellular deposition of toxic TTR aggregates in various organs. Despite recent advances regarding the elucidation of the molecular mechanisms underlying TTR misfolding and pathogenic self-as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ferreira, Nelson, Pereira-Henriques, Alda, Attar, Aida, Klärner, Frank-Gerrit, Schrader, Thomas, Bitan, Gal, Gales, Luís, Saraiva, Maria João, Almeida, Maria Rosário
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3996111/ https://www.ncbi.nlm.nih.gov/pubmed/24459092 http://dx.doi.org/10.1007/s13311-013-0256-8

Ejemplares similares

Safety and pharmacological characterization of the molecular tweezer CLR01 – a broad-spectrum inhibitor of amyloid proteins’ toxicity
por: Attar, Aida, et al.
Publicado: (2014)

Molecular Lysine Tweezers Counteract Aberrant Protein Aggregation
por: Hadrovic, Inesa, et al.
Publicado: (2019)

Uncovering the Neuroprotective Mechanisms of Curcumin on Transthyretin Amyloidosis
por: Ferreira, Nelson, et al.
Publicado: (2019)

Transthyretin chemical chaperoning by flavonoids: Structure–activity insights towards the design of potent amyloidosis inhibitors
por: Ferreira, Nelson, et al.
Publicado: (2015)

Amyloid β-Protein Assembly: The Effect of Molecular Tweezers CLR01 and CLR03
por: Zheng, Xueyun, et al.
Publicado: (2015)

Inhibition of Mutant αB Crystallin‐Induced Protein Aggregation by a Molecular Tweezer
por: Xu, Na, et al.
Publicado: (2017)

Lysine-selective molecular tweezers are cell penetrant and concentrate in lysosomes
por: Li, Zizheng, et al.
Publicado: (2021)

Modulation of the Mechanisms Driving Transthyretin Amyloidosis
por: Bezerra, Filipa, et al.
Publicado: (2020)

Curcumin: A multi-target disease-modifying agent for late-stage transthyretin amyloidosis
por: Ferreira, Nelson, et al.
Publicado: (2016)

The molecular tweezer CLR01 improves behavioral deficits and reduces tau pathology in P301S-tau transgenic mice
por: Di, Jing, et al.
Publicado: (2021)

Interleukin-1 signaling pathway as a therapeutic target in transthyretin amyloidosis
por: Gonçalves, Nádia Pereira, et al.
Publicado: (2014)

Correction to: The molecular tweezer CLR01 improves behavioral deficits and reduces tau pathology in P301S-tau transgenic mice
por: Di, Jing, et al.
Publicado: (2021)

Differential expression of Cathepsin E in transthyretin amyloidosis: from neuropathology to the immune system
por: Gonçalves, Nádia Pereira, et al.
Publicado: (2017)

Tegsedi (Inotersen): An Antisense Oligonucleotide Approved for the Treatment of Adult Patients with Hereditary Transthyretin Amyloidosis
por: Gales, Luís
Publicado: (2019)

Hereditary transthyretin amyloidosis overview
por: Manganelli, Fiore, et al.
Publicado: (2020)

A molecular tweezer antagonizes seminal amyloids and HIV infection
por: Lump, Edina, et al.
Publicado: (2015)

Epigallocatechin-3-Gallate as a Potential Therapeutic Drug for TTR-Related Amyloidosis: “In Vivo” Evidence from FAP Mice Models
por: Ferreira, Nelson, et al.
Publicado: (2012)

Cavity filling mutations at the thyroxine-binding site dramatically increase transthyretin stability and prevent its aggregation
por: Sant’Anna, Ricardo, et al.
Publicado: (2017)

Transthyretin cardiac amyloidosis
por: Tomoaia, Raluca, et al.
Publicado: (2021)

Transthyretin cardiac amyloidosis
por: Porcari, Aldostefano, et al.
Publicado: (2022)

Supramolecular Mechanism of Viral Envelope Disruption by Molecular Tweezers
por: Weil, Tatjana, et al.
Publicado: (2020)

Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage
por: Law, Steven, et al.
Publicado: (2020)

Hereditary transthyretine amyloidosis in Slovenia
por: Zidar, Janez
Publicado: (2015)

Multidisciplinary Approaches for Transthyretin Amyloidosis
por: Koike, Haruki, et al.
Publicado: (2021)

Clinical model for Hereditary Transthyretin Amyloidosis age of onset prediction
por: Pedroto, Maria, et al.
Publicado: (2023)

EGCG-Mediated Protection of Transthyretin Amyloidosis by Stabilizing Transthyretin Tetramers and Disrupting Transthyretin Aggregates
por: Zou, Huizhen, et al.
Publicado: (2023)

Monitoring the Patient with Retinal Angiopathy Associated with Hereditary Transthyretin Amyloidosis: Current Perspectives
por: Marques, João Heitor, et al.
Publicado: (2022)

Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS)
por: Damy, Thibaud, et al.
Publicado: (2019)

Sex Differences in Wild-Type Transthyretin Amyloidosis: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)
por: Campbell, Courtney M., et al.
Publicado: (2022)

Quantitative SPECT/CT Parameters in the Assessment of Transthyretin Cardiac Amyloidosis—A New Dimension of Molecular Imaging
por: Gherghe, Mirela, et al.
Publicado: (2023)

Extracellular Vesicles Contribute to the Metabolism of Transthyretin Amyloid in Hereditary Transthyretin Amyloidosis
por: Yamaguchi, Hiroki, et al.
Publicado: (2022)

Frequency of hereditary transthyretin amyloidosis among elderly patients with transthyretin cardiomyopathy
por: Maestro‐Benedicto, Alba, et al.
Publicado: (2022)

Recent advances in transthyretin amyloidosis therapy
por: Ueda, Mitsuharu, et al.
Publicado: (2014)

Evolving landscape in the management of transthyretin amyloidosis
por: Hawkins, Philip N., et al.
Publicado: (2015)

Screening for hereditary transthyretin amyloidosis in Bulgaria
por: Nakov, Radislav, et al.
Publicado: (2021)

A Late Diagnosis of Transthyretin Amyloidosis
por: Pfirman, Kristopher S, et al.
Publicado: (2022)

Transthyretin Cardiac Amyloidosis: Underrecognized in the Underrepresented
por: Leedy, Douglas J., et al.
Publicado: (2023)

Spectrum of transthyretin gene mutations and clinical characteristics of Polish patients with cardiac transthyretin amyloidosis
por: Gawor, Monika, et al.
Publicado: (2022)

Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity
por: Sant'Anna, Ricardo, et al.
Publicado: (2016)

Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis
por: Butler, James S., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_7lgcsr6jsa7qsdp5k5f0583loc